trial

Estradiol as add-on to Antipsychotics

NCTId NCT04093518
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 100 (estimated)
Sponsored by Tangent Data Srl
Primary completion 2020-10-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2019-12-02
Primary completion
2020-10-15
Eligibility
FEMALE · 38 Years · 48 Years

Interventions & indications

Drugs
Estradiol

Sponsors

Tangent Data SrlLead Sponsor
Stanley Medical Research InstituteCollaborator
MediStat Ltd.Collaborator
PCI pharma services (formerly BIOTEC SERVICES INTERNATIONAL LIMITED)Collaborator
S.C. IMUNOTEHNOMED S.R.L.Collaborator
Tangent Data SrlCollaborator

Investigators

1
Mark A Frye, M.D.Principal Investigator

Sites

1 total
Chisinau, Moldova

Linked catalysts

1
Estradiol as add-on to Antipsychotics — primary completion2020-10-15

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE3
Primary Completion Date
2020-10-15
Status
UNKNOWN
relationships
The graph out of here
drug
Estradiol
drug
lead_sponsor
Tangent Data Srl
company
collaborator
Stanley Medical Research Institute
company
MediStat Ltd.
company
indication
Schizophreniform Disorders
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Mark A Frye, M.D.
person